GLPwatch
Exenatide for once-weekly administration.
Drug Ther Bull · 2012
Last updated 2026-05-28Exenatide is a GLP-1 drug used to treat type 2 diabetes. A twice-daily injectable version was approved in 2006, while Bydureon is a once-weekly injectable version of the same drug.
AI summary of the abstract below.
| Journal | Drug Ther Bull, 2012 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.04 |
| NIH percentile | 4 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
▾Exenatide is a glucagon-like peptide 1 (GLP-1) agonist used in the management of people with type 2 diabetes. A twice-daily injectable formulation (▾Byetta - Eli Lilly) was licensed in 2006. ▾Bydureon (Eli Lilly) is a prolonged-release injectable formulation that allows once-weekly administration. Here we discuss the place of Bydureon in the management of type 2 diabetes mellitus.
Verbatim abstract via PubMed 22789767 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.